News | Atrial Fibrillation | December 14, 2022

Field Medical and CardioNXT Collaborate to Deliver Novel Integration of Focal Pulsed Field Ablation And 3D Mapping & Navigation For Treatment of Cardiac Arrhythmias

Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry 

Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry

December 14, 2022 —  Field Medical, Inc. and CardioNXT, Inc. announce a strategic collaboration to provide the first-of-its-kind, purpose built, focal pulsed field ablation (PFA) therapy integrated seamlessly with 3D mapping & navigation.  

Both teams will harness decades of experience in pioneering novel PFA and navigation product solutions in various medical therapy applications. 

"PFA has generated much excitement in the treatment of atrial fibrillation due to an improved safety profile and procedural workflow. However, most of the first generation PFA technologies today are repurposed from other applications and suffer from significant limitations outside a subset of AFib procedures," said Dr. Steven Mickelsen, CEO, Field Medical. "This collaboration brings together second generation focal PFA and AI-based cardiac mapping—a combination set to revolutionize catheter ablation across the full spectrum of treatable arrhythmias." 

This new collaboration will accelerate development of novel integrated solutions aimed at improving safety and efficacy while minimizing need for x-rays used in cardiac catheter ablation, a market that has grown to $6B per year globally. Accurate navigation is critical to the heart rhythm treatment especially outside the atria where magnetic localization can dramatically improve positioning during the treatment of life threatening ventricular tachycardia. 

"We are excited to collaborate with Field Medical to build a purpose-built system from the ground up that incorporates PFA, Contact Force Sensing, Electromagnetic Localization, and AI-enabled mapping capabilities," said Jerome Edwards, CEO, CardioNXT. "We believe this will create a first of its kind completely integrated total solution to identify sources of cardiac arrhythmias and deliver therapy to those targets more efficaciously than ever before." 

For more information: https://www.fieldmedicalinc.com/ 

For more information: www.verseon.com 


Related Content

News | Cardiovascular Business

June 18, 2024 — Carestream Health recently secured an agreement with Distribuidora Diagnostica Medica SAC (DMD), a ...

Home June 18, 2024
Home
News | Cardiovascular Business

June 13, 2024 — Frederick St. Goar, MD, medical director at the Norma Melchor Heart & Vascular Institute, was ...

Home June 13, 2024
Home
News | Cardiovascular Business

June 11, 2024 — Columbia University Irving Medical Center’s CUIMC Division of Cardiology has launched the Mitral and ...

Home June 11, 2024
Home
Feature | Cardiovascular Business

June 7, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of the ...

Home June 07, 2024
Home
News | Cardiovascular Business

June 5, 2024 — Edwards Lifesciences announced it has entered into a definitive agreement to sell its Critical Care ...

Home June 05, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a look at the Top 10 pieces of content viewers were reading during the month of May. 1. American College of ...

Home June 04, 2024
Home
News | Cardiovascular Business

May 31, 2024 — Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part ...

Home May 31, 2024
Home
News | Cardiovascular Business

May 22, 2024 — Voiant (USA) and Thirona (The Netherlands) announced they have entered a global commercial partnership ...

Home May 22, 2024
Home
News | Cardiovascular Business

May 14, 2024 — GE HealthCare, a leading global medical technology, pharmaceutical diagnostics and digital solutions ...

Home May 14, 2024
Home
News | Cardiovascular Business

May 6, 2024 — SMT (Sahajanand Medical Technologies), a leading medical device company at the forefront of innovative ...

Home May 06, 2024
Home
Subscribe Now